Pathophysiology
The study [PMID:25555960] notes that the esophageal wall in Barrett's esophagus exhibits specific alterations like musculofibrous thickening and duplication of the muscularis mucosae, which impact surgical techniques and outcomes.
Diagnosis
The study highlighted that the complexity mix of Barrett's lesions varied significantly between different clinics, suggesting potential selection biases or differences in clinical assessment [PMID:18522640].
Management
In the Chemoprevention for Barrett's Esophagus Trial (CBET), 309 QE studies were conducted without adverse events, demonstrating QE's safety and utility in measuring changes in Barrett's esophagus lesion areas from baseline to 1 year [PMID:18522640].
This case report [PMID:25555960] demonstrates the successful use of a thoracoscopic approach for emergency surgical intervention in a patient with spontaneous perforation of a Barrett's ulcer, highlighting its potential as a viable management strategy.
In a randomized trial [PMID:21385192], esomeprazole 40 mg twice daily led to significant decreases in Ki67 and COX-2 expression, indicative of reduced cellular proliferation and inflammation, while pantoprazole did not show similar effects.
The study [PMID:21385192] demonstrated that esomeprazole treatment for 12 months significantly increased apoptosis in Barrett's esophagus patients, suggesting a potential anti-neoplastic effect.
Complications
The paper [PMID:25555960] underscores that spontaneous perforation of a Barrett's ulcer is associated with significant life-threatening complications, emphasizing the urgent need for surgical intervention.
Prognosis & Follow-up
QE measurements indicated that intra-patient differences in lesion surface area over time were smaller than those observed between randomly selected patients, underscoring the importance of consistent monitoring in individual patient management [PMID:18522640].
Patients treated with esomeprazole [PMID:21385192] showed normal acid exposure times on 24-hour pH monitoring, indicating effective acid suppression compared to those on pantoprazole.
References
1 Shar AO, Gaudard MA, Heath EI, Forastiere AA, Yang VW, Sontag SJ. Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2008. link 2 Ashrafian H, Navarro-Sanchez A, Athanasiou T, Sherman DI, Isla A. Thoracoscopic esophageal repair of a spontaneous Barrett's ulcer perforation. The Annals of thoracic surgery 2015. link 3 de Bortoli N, Martinucci I, Piaggi P, Maltinti S, Bianchi G, Ciancia E et al.. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year. Alimentary pharmacology & therapeutics 2011. link